Aardvark Therapeutics, Inc. Common Stock (AARD) is a publicly traded Healthcare sector company. As of May 21, 2026, AARD trades at $4.40 with a market cap of $95.12M and a P/E ratio of -1.33. AARD moved -1.49% today. Year to date, AARD is -67.70%; over the trailing twelve months it is -61.00%. Its 52-week range spans $3.35 to $19.58. Analyst consensus is buy with an average price target of $15.14. Rallies surfaces AARD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aardvark to Unblind ARD-101 Data After FDA’s Full Clinical Hold: FDA placed a full clinical hold on Aardvark Therapeutics’ ARD-101 IND, suspending its Phase 3 HERO trial for Prader-Willi hyperphagia and the open-label extension study. The company will unblind data from 68 HERO and 19 extension patients to evaluate efficacy and safety, and holds $91.2 million to fund operations into mid-2027.
| Metric | Value |
|---|---|
| Price | $4.40 |
| Market Cap | $95.12M |
| P/E Ratio | -1.33 |
| EPS | $-3.21 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.58 |
| 52-Week Low | $3.35 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $-1.18M |
| Net Income | $-69.87M |
| Gross Margin | 0.00% |
10 analysts cover AARD: 0 strong buy, 5 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.14.